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Introduction: Clinical effects of furosemide (F) and ethacrynic acid (EA) continuous infusion on urine output (UO),
fluid balance, and renal, cardiac, respiratory, and metabolic function were compared in infants undergoing surgery
for congenital heart diseases.
Methods: A prospective randomized double-blinded study was conducted. Patients received 0.2 mg/kg/h
(up to 0.8 mg/kg/h) of either F or EA.
Results: In total, 38 patients were enrolled in the F group, and 36, in the EA group. No adverse reactions were
recorded. UO at postoperative day (POD) 0 was significantly higher in the EA group, 6.9 (3.3) ml/kg/h, compared
with the F group, 4.6 (2.3) ml/kg/h (P = 0.002) but tended to be similar in the two groups thereafter. Mean
administered F dose was 0.33 (0.19) mg/kg/h compared with 0.22 (0.13) mg/kg/h of EA (P < 0.0001). Fluid balance
was significantly more negative in the EA group at postoperative day 0: −43 (54) ml/kg/h versus −17 (32) ml/kg/h
in the F group (P = 0.01). Serum creatinine, cystatin C and neutrophil gelatinase-associated lipocalin levels and
incidence of acute kidney injury did not show significant differences between groups. Metabolic alkalosis occurred
frequently (about 70% of cases) in both groups, but mean bicarbonate level was higher in the EA group: 27.8 (1.5) M in
the F group versus 29.1 (2) mM in the EA group (P = 0.006). Mean cardiac index (CI) values were 2.6 (0.1) L/min/m2 in
the F group compared with 2.98 (0.09) L/min/m2 in the EA group (P = 0.0081). Length of mechanical ventilation was
shorter in the EA group, 5.5 (8.8) days compared with the F group, 6.7 (5.9) (P = 0.06). Length of Pediatric Cardiac
Intensive Care Unit (PCICU) admission was shorter in the EA group: 14 (19) days compared with 16 (15) in the
F group (P = 0.046).
Conclusions: In cardiac surgery infants, EA produced more UO compared with F on POD0. Generally, a smaller
EA dose is required to achieve similar UO than F. EA and F were safe in terms of renal function, but EA caused a
more-intense metabolic alkalosis. EA patients achieved better CI, and shorter mechanical ventilation and PCICU
admission time.
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Loop diuretics (LDs) are frequently administered to
critically ill children to manage the high fluid load that
is prescribed daily and to control fluid balance. LD
pharmacologic action is exerted at the thick ascending
limb of Henle loop by reversibly blocking one of the
chloride-binding sites of the Na+/K+/2 Cl− carrier. Conse-
quently, reabsorption of filtered sodium is inhibited. This
intense natriuresis promotes an increased diuresis [1]. In
Pediatric Intensive Care Units (PICUs), LDs are routinely
administered by either intermittent or continuous intra-
venous infusions [2]. The vast majority of pediatric cardiac
surgery patients receive LDs in the preoperative, intraop-
erative, and postoperative phases. LDs are the mainstay of
therapy in children with congenital heart disease (CHD),
particularly in the near-postoperative phase: they are es-
sential for the management of fluid loading and the leak
syndrome occurring after cardiopulmonary bypass (CPB)
and of the high fluid administration needed for postopera-
tive therapies and nutrition [3]. Postoperative fluid over-
load in patients with congenital heart disease has been
associated with increased occurrence of acute kidney in-
jury (AKI), prolonged length of mechanical ventilation,
worsened respiratory function, and delayed discharge
from the PICU [4-7].
Timely treatment of fluid excess has never been pro-
spectively examined: diuretics, however, are recommended
for management of fluid overload in adults and children
[8]. Furthermore, in patients with cardiac dysfunction,
LDs are needed both for left ventricular failure (to de-
crease hypervolemia, ventricular filling pressures, and
pulmonary congestion) and right ventricular failure (to
control fluid accumulation and systemic venous con-
gestion, both of which are causes of renal and splanch-
nic organ dysfunction) [9]. The presence of well-known
side effects, however, including metabolic alkalosis, the
risk of neurohormonal activation, systemic vasocon-
striction, electrolyte disturbances, impairment of renal
function, and perhaps, worse clinical outcomes, may
lead to arguments against an aggressive diuretic ap-
proach in these patients [10]. It was previously shown
that continuous infusion of furosemide causes a gradual
increase in urine output (UO) that is significantly su-
perior, in terms of total daily diuresis, to the unpredict-
able urine volume secondary to intermittent boluses
[11]. Commonly administered LDs in PICUs are fur-
osemide, bumetanide, and ethacrynic acid. In our insti-
tution, furosemide and ethacrynic acid are administered
without any specific protocol. Although few studies
exist on the relative pharmacokinetic properties of
these two drugs [12], ethacrynic acid is considered to
be 30% less potent than furosemide [12]. The exact effect
on diuresis, the appropriate dose of these drugs’ continu-
ous infusion, the difference between the pharmacologiceffects of furosemide and ethacrynic acid, and their side
effects have never been addressed previously in pediatric
patients with CHD.
The aim of this study was to compare the clinical ef-
fects of a continuous infusion of furosemide with a con-
tinuous infusion of ethacrynic acid on UO, control of
fluid balance, and on renal, cardiac, respiratory, and
metabolic function in a population of infants undergoing
surgery for CHD.
Methods
A prospective randomized double-blind study (the
Furocrynic Study) was conducted at the Pediatric Cardiac
Intensive Care Unit (PCICU), Ospedale Bambino Gesù,
Rome, Italy, from June 2012 to November 2013
(NCT01628731). Consecutive infants undergoing elect-
ive surgery for CHD and who had signs of fluid over-
load or leak syndrome, according to the attending
physician at PCICU admission, were enrolled. To assess
roughly fluid loading received in the operating room
(apart from blood loss and transfusions), intraoperative
fluid balance was assessed and indexed on preoperative
patients’ weight ((intraoperative fluid in-intraoperative
urine output)/patients’ body weight × 100). It is almost
impossible to evaluate intraoperative blood loss pre-
cisely, because of suction into big reservoirs, blood col-
lected into cell savers, and blood absorbed by dressings;
furthermore, blood-derivate transfusion bag number is
reported only in our clinical charts, avoiding any exact
calculation of infused fluids. Exclusion criteria were the
presence of known preoperative renal dysfunction (need
for preoperative dialysis or presence of renal malforma-
tions), preoperative chronic (<14 days) LD administration,
need for extracorporeal membrane oxygenation at PCICU
admission, and time of admission to the PCICU >60 mi-
nutes. The study could be interrupted at any time if the at-
tending physician recorded any sign of adverse reaction
related to the diuretic infusion (allergy, hemodynamic in-
stability, arrhythmias).
Objectives
The primary objective of this study was to verify the su-
periority of ethacrynic acid compared with furosemide in
improving patients’ postoperative UO during the first
postoperative day (POD0). The primary end point was to
assess the mean daily UO (expressed in ml/kg/h) in POD0
(from PCICU admission to 7 AM of the next morning).
Secondary objectives were (a) to verify the superiority
of ethacrynic acid compared with furosemide in improv-
ing patients’ postoperative UO during the first 72 hours,
including the mean daily UO (expressed in ml/kg/h) in
the first and second PODs (not only POD0); (b) to com-
pare the daily dose required by each LD to achieve re-
spective UOs in the first 3 PODs by indexing mean UO
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measure fluid balance in the first 72 hours in the two
groups; (d) to compare renal function after infusion of
ethacrynic acid and furosemide by evaluating the occur-
rence of acute kidney injury (AKI) and the mean levels
of serum creatinine (sCr), cystatin C (CysC), and whole
blood neutrophil gelatinase-associated lipocalin (NGAL)
in the two groups; (e) to compare the occurrence of hypo-
kalemia and metabolic alkalosis in the two groups; (f) to
compare the effects of the two LDs on hemodynamic and
respiratory functions by measuring mean cardiac index
(CI), mean ratio of PaO2 over fractional inspired oxygen
(PaO2/FIO2), mean length of mechanical ventilation, and
mean length of PCICU admission (LOA).
To examine whether any association was present be-
tween diuretic dose and other variables (weight, Aristotle
score, vasoactive inotrope score, CPB duration, length of
mechanical ventilation, LOA, creatinine values, UO, UO/
diuretic dose), we conducted a secondary analysis compar-
ing two significantly different subgroups of our patients:
those who interrupted (any) diuretic continuous infusion
on POD1 (early stoppers,ESs) and those who continued a
full continuous diuretic dose (0.2 mg/kg/h or more) up to
POD3 (late stoppers, LSs).
Interventions
Enrolled patients were randomized to receive either
0.2 mg/kg/h of furosemide or an equivalent dose of
ethacrynic acid in a double-blind fashion. The attending
physicians were allowed to increase the drugs up to a
corresponding dose of 0.8 mg/kg/h (as done in clinical
practice, according to institutional protocols). After
72 hours, data collection was interrupted, and the diur-
etic was administered openly. Physicians were permitted
to decrease or stop the continuous infusion if clinically
indicated, at any time after enrolment, during the stud-
ied period, or to convert the continuous infusion to
intermittent boluses: however, they were required to spe-
cify the reason for interruption. The only clinical goal
that clinicians were requested to target, if possible, was
an even or negative fluid balance at POD0. Furthermore,
bolus doses were always 1 mg/kg, and the attending
physician prescribed the dosing interval (6, 8, or
12 hours). In all other cases, attending physicians were
free to act according to everyday practice.
Randomization procedure
After patient enrollment, a nurse who was not involved
in the care of the study patient prepared the diuretic in-
fusion in an effort to maintain blinding of the study drug
to the bedside nurse and clinician. The drug was diluted
to provide a consistent rate of 0.5 ml/hour and dose of
0.2 mg/kg/hour to all patients and held in black syringes
labeled “diuretic study”. The allocation sequence wasgenerated by a computerized random-number generator.
If the attending physician wanted to administer the
study drug intermittently, boluses were prepared blinded
to the bedside nurse and clinician.Data collection
Demographic data, diagnosis, type and risk of surgery
(Aristotle score), and intraoperative information (CPB
and cross-clamp length, need for deep hypothermic cir-
culatory arrest, delayed sternal closure) were recorded at
patient enrollment. Each enrolled patient had the same
set of data available at every time point (PCICU arrival,
POD0, POD1, POD2): hemodynamic data (heart rate;
systolic, diastolic, and mean arterial pressure; left atrial
pressure; central venous pressure; cardiac index), labora-
tory data (sCr, CysC, NGAL), blood gas analysis data
(pH, SaO2, SvO2, bicarbonate concentration, base excess,
lactates), and the amount of administered vasoactive
drugs, including vasoactive inotropic score (VIS). PaO2/
FIO2 was recorded at all time points. At POD0, POD1,
and POD2 UO, fluid balance and mean daily diuretic
dose (expressed in mg/kg/h both for continuous infusion
and for intermittent boluses) were also recorded. Need
for dialysis, length of mechanical ventilation, and LOA
were documented for all patients as outcome measures.
AKI was defined according to the pediatric RIFLE
(pRIFLE) score (acronym of Risk for renal dysfunction,
Injury to the kidney, Failure of kidney function, Loss of
kidney function, and End-stage renal disease), recently
proposed for AKI diagnosis and classification in children
based on glomerular filtration rate and UO criteria [13].
Hypokalemia was defined as a potassium level below
2.6 mM. Metabolic alkalosis was defined as a pH above
7.45 and bicarbonate concentration above 29M or a
base excess level above +5. Whole-blood NGAL was
measured by using a point-of-care immunoassay (Biosite
Inc., San Diego, CA, USA).
VIS was calculated as follows: dopamine (μg/kg/min) +
milrinone (μg/kg/min) × 10 + epinephrine (μg/kg/min) ×
100 + vasopressin (UI/kg/min) × 10,000 [14]. CI was mea-
sured with the Pressure Recording Analytical Method
(PRAM) [15]. This is a minimally invasive hemodynamic
monitoring system based on mathematical analysis of the
invasive arterial waveform recorded at a high sampling
rate (1,000 Hz). The area under the pressure wave is ex-
amined during the whole cardiac cycle, including the post-
dicrotic notch phase, and it is used to assess the patients’
stroke index. PRAM monitoring requires both an arterial
waveform without artifacts and the correct identification
of the dicrotic notch (it cannot be used in cases of
under- or overdamping). The PRAM monitor automat-
ically records each minute’s CI and makes it available
for download.
Table 1 Demographic and baseline (PCICU admission)
data
Furosemide Ethacrynic acid P
Number of patients 38 36 -
Demographic
Age (days) 104 (180) 135 (181) 0.57
Weight (kg) 4.6 (3.9) 4.2 (3.1) 0.63
Body surface area (m2) 0.27 (0.16) 0.25 (0.11) 0.46
Correction/palliation 11/38 (27%) 10/36 (28%) 0.96
Neonates 18/38 (45%) 17/36 (47%) 0.99
Aristotle score 9.5 (2.5) 9.7 (2.5) 0.53
CPB (min) 187 (70) 204 (102) 0.43
OFF pump (n) 5/38 (12.5%) 2/36 (6%) 0.26
XClamp (minutes) 102 (56) 100 (75) 0.88
OFF XClamp (n) 4/33 (12%) 2/34 (6%) 0.67
DHCA (n) 7/29 (24%) 7/32 (22%) 0.83
Baseline (PCICU admission)
Heart rate (beats/min) 162 (20) 154 (32) 0.25
Syst art press (mm Hg) 77 (13) 81 (19) 0.35
LAP (mm Hg) 6.9 (2.6) 7.5 (1.9) 0.41
CVP (mm Hg) 9.5 (2.9) 9.5 (2.8) 0.98
CI (L/min/m2) 2.5 (0.5) 2.8 (0.8) 0.19
VIS 22 (18) 21 (11) 0.76
Cerebral NIRS (%) 54 (18) 57 (16) 0.50
Renal NIRS (%) 68 (20) 69 (19) 0.88
sCr (mg/dl) 0.58 (0.20) 0.57 (0.17) 0.78
CysC (mg/dl) 1.08 (0.4) 1.16 (0.3) 0.58
NGAL (pg/ml) 89 (57) 93 (69) 0.78
pH 7.45 (0.1) 7.45 (0.08) 0.78
HCO3− (M) 25 (3.6) 26 (2.5) 0.55
BE 1.29 (4.8) 1.88 (3.3) 0.57
Lactates (mM) 5.6 (3.9) 6.3 (3.2) 0.46
SaO2 (%) 92 (11) 88 (18) 0.27
SvO2 (%) 60 (21) 57 (16) 0.47
PaO2/FIO2 192 (149) 141 (124) 0.15
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Intention to treat was applied, and all enrolled patients
were considered for statistical analysis at the end of the
study. The χ2 test was used to compare categoric vari-
ables. The Student t test was used to compare continu-
ous variables. Two-way analysis of variance for repeated
measures was used to compare continuous variables
over time between the two groups, with the Bonferroni
post hoc test for each time point. All data are presented
as mean and standard deviation (SD). A P value <0.05
was considered significant. Statistical analysis was per-
formed by using the GraphPad Prism 5.0 software pack-
age (Graph-Pad Software, San Diego, CA, USA).
The study was powered on the primary outcome based
on previously available institutional data. The number of
patients needed to detect a 1-ml/kg/h difference in UO
between the two groups at POD0, with an 80% statistical
power and an alpha error of 0.05, was calculated to be
35 for each study group. We planned to enroll a total of
76 patients to accommodate dropouts. An interim ana-
lysis was planned after the enrollment of 40 patients,
and a stopping rule was determined in case of major
morbidity being detected in this phase.
The institutional review board of the Bambino Gesù
Children’s Hospital approved the protocol [Prot n.
623RA]. Informed consent was obtained from both par-
ents. The Furocrynic trial was recorded at Clinicaltrial.
gov [NCT01628731].
Results
Demographic and other study data
Seventy-six patients were enrolled. Two patients were
excluded from the EA group after enrollment (and not
included in the analysis). The first was excluded because
the child was enrolled after 60 minutes from PCICU ad-
mission; the second one was excluded because the par-
ents withdrew the informed consent after enrollment.
Data from 74 patients were analyzed: 38 in the furosem-
ide (F) group and 36 in the ethacrynic acid (EA) group.
The groups were adequately matched for demographic
and baseline values (Table 1). Average (SD) age was 104
(180) days in the F group and 135 (181) days in the EA
group (P = 0.57). Average Aristotle score was 9.5 (2.5) in
the F group and 9.7 (2.5) in the EA group (P = 0.53).
Average VIS at baseline (PCICU arrival) was 22 (18) in
the F group and 21 (11) in the EA group (P = 0.76).
Average fluid overload (excluding bleeding and post-
CPB transfusions) was not significantly different in the
two populations: 6% (eight) in the EA group and 4%
(five) in the F group (P = 0.45).
The study infusion durations were initially similar in
the two groups: from PCICU admission to the end of
POD0, the F group received the continuous infusion for
13 (2) hours, whereas the EA received the study drug for12 (3) hours (P = 0.08). Continuous infusion was inter-
rupted for clinical reasons before the end of the study
period in 11 F patents and in 23 EA patients (P = 0.001):
in particular, at the end of POD0, all enrolled patients
were still receiving continuous infusions in both groups,
whereas at the end of POD1 and POD2, eight and 14
EA patients, respectively, and three and nine F patients
were switched to diuretic boluses administration. The
reasons for interruption of continuous infusion, as re-
ported by attending clinicians, were polyuria (50%) and
excess of negative fluid balance (50%), with no difference
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the continuous infusion received the study diuretic (in
boluses, at a lower daily dosage) for the whole 72-hour
study period. The diuretic administration was never dis-
continued as a result of suspected adverse reactions in
any patient at any time point.
Results on renal function
The primary end point (UO at POD0) was 6.9 (3.3) ml/
kg/h in the EA group, which was significantly higher
than 4.6 (2.3) ml/kg/h (P = 0.002) in the F group. UO in
the following days tended to be similar in the two
groups, without significant differences (Figure 1A). How-
ever, mean diuretic dose was significantly different in the
two groups throughout the study period: overall, mean
administered furosemide was 0.33 (0.19) mg/kg/h,
whereas mean administered EA was 0.22 (0.13) mg/kg/h
(P < 0.0001): it can be assumed that for a similar UO,
about 30% less EA was needed. A daily diuretic dose
above 0.4 mg/kg/h was administered to three patients in
the L group (two of these received 0.8 mg/kg/h for
24 hours, and one received 0.5 mg/kg/h for 48 hours)
and to one patient in the EA group (0.5 mg/kg/h forFigure 1 Urine output (UO) levels expressed in ml/kg/h in the
furosemide (F) and ethacrynic acid (EA) groups. In (A) Absolute
UO levels.are depicted. In (B), UO indexed on diuretic dose are
indicated. *P < 0.05. POD, postoperative day. Data are expressed as
average and standard deviation.24 hours). The mean UO levels indexed over mean
diuretic dose were significantly different in the two
groups at every time point (<0.01) (Figure 1B). Fluid
balance was significantly more negative in the EA
group at POD0: −43 (54) ml/kg/h compared with −17
(32) ml/kg/h (P = 0.01) in the F group. Thereafter, fluid
balance was similar in the two groups (Figure 2).
Renal function was apparently unaffected by the use of
either diuretic. SCr levels only changed significantly with
respect to preoperative values (P = 0.0001). However, dif-
ferences between the two groups were not significant
(P = 0.54) (Figure 3). CysC and NGAL levels showed
similar levels in the two groups over time, without sig-
nificant differences overall. NGAL average levels were
102.9 (10.87) in the F group versus 112.7 (13.4) ng/ml in
the EA group (P = 0.25). CysC average levels were 1.2
(0.1) mg/dl in the F group versus 1.3 (0.1) mg/dl in the
EA group (P = 0.09). Overall incidence of AKI according
to pRIFLE was 73% in the F group and 82% in the EA
group (P = 0.31). The incidence of Injury level (according
to pRIFLE) was 35% in the F group and 41% in the EA
group (P = 0.58). No patient in either group was diagnosed
with Failure level or required dialysis. Creatinine at
PCICU discharge was 0.35 (0.14) in the F group and 0.34
(0.14) in the EA group. Average percentage difference with
baseline creatinine values was −22% (25) and −22% (19) in
the F and EA groups, respectively (P = 0.99).
Results on other outcomes
No arrhythmic episode linked to electrolyte disorders
was recorded during the study period. Hypokalemia was
common: in total, 91 episodes in the F group and 88 in
the EA group were recorded in the whole population
during the entire study period. Among those who expe-
rienced at least one episode of low potassium levels,
hypokalemia occurred 2.5 times per day in both groups
(P = 0.9). Overall, no significant difference was noticedFigure 2 Fluid balance (FB) per kilogram of patient body weight
in the three study days in the furosemide (F) and ethacrynic acid
(EA) groups. *P < 0.05. POD, postoperative day. Data are expressed as
average and standard deviation.
Figure 3 Serum creatinine (SCr) levels in the furosemide (F) and
ethacrynic acid (EA) groups: although significant increase was
evident from preoperative (PRE-OP) to Pediatric Cardiac Intensive
Care Unit admission (PCICU admiss) levels, no difference was
evident between the two study groups over time. *P < 0.05.
POD, postoperative day. Data are expressed as average and standard
deviation.
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kalemic episodes during each of the three study days be-
tween the F and the EA group (POD 0, 35% versus 44%;
POD 1, 33% versus 32%; POD 2, 40% versus 26%; P =
0.83). Metabolic alkalosis was also common; 70% of F
group patients and 74% of EA group patients experi-
enced at least one metabolic alkalosis event during the
study period (p = 0.35). Mean bicarbonate level increased
significantly during the first days of the study (p = 0.0001),
and appeared to be slightly although significantly higher
in the EA group: 27.8 (1.5) mmol/L in the F group versus
29.1 (2) mmol/L in the EA group (p = 0.006). CI was sig-
nificantly different between the two groups considering
that mean VIS at PCICU admission was similar (p = 0.29).
Throughout the three study days, it appeared to be im-
proved in the EA group with respect to the F group
(p = 0.0081): mean CI values were 2.6 (0.1) L/min/m2 in
the F group compared to 2.98 (0.09) L/min/m2 in the
EA group. Length of mechanical ventilation was 5.5
(8.8) days in the EA group compared to 6.7 (5.9) in the
F group (p = 0.06). PaO2/FIO2 at the end of POD 0
(when all patients were still ventilated) was similar: 179
(113) in the F group versus 160 (115) in the EA group
(p = 0.49). LOA was shorter in the EA group: 14 (19) in
the F group versus 16 (15) in the EA group (p = 0.046).
No patient died during the study period.
Results on diuretic dose
ES group was composed by 11 patients, of which 8 from
EA group and 3 from F group, whereas 7 children werein the LS group (3 in the EA group and 4 in the F
group). ES received a significantly lower amount of diur-
etic: 0.14 (0.09) vs 0.49 (0.17) mg/kg/h (p = 0.0001). ES
patients were significantly bigger, had lower Aristotle
score and significantly lower VIS, a significantly lower
CPB duration, a significantly lower length of mechanical
ventilation, an insignificantly lower LOA (Table 2). Inter-
estingly, whereas UO and creatinine values did not show
significant differences between the two groups over time,
UO/diuretic dose was significantly different, displaying
about double values with respect to LS at all the time
points (p = 0.0006) (Table 2).
Discussion
Current guidelines recommend using the minimum dose
of LD required to keep the patient free of signs and
symptoms of congestion [16]. Although the once-daily
use of furosemide might be convenient for some pa-
tients, it is not optimal from a pharmacodynamics per-
spective, since daily dosing results in a long period of
sodium avidity by the kidney when therapeutic diuretic
concentrations are not present. More frequent furosem-
ide dosing serves to limit this “rebound” effect [17]. The
use of continuous infusion LD has attracted tremendous
attention. This method has proven beneficial in patients
with a diuretic resistance or tolerance to conventional
intermittent therapy [18]. Several potential advantages of
continuous infusion LD have been identified, including
decreased electrolyte loss secondary to a lower dosage of
diuretic, production of a more reliable urine flow, and
decreased alterations in fluid balance [19]. Luciani et al.
[11] found that the administration of LD via continuous
infusion produced a more controlled diuresis with less
variation in hemodynamic parameters.
Furosemide has been the most widely studied loop diur-
etic with regard to administration via continuous infusion
in children [20]. In a study by van der Vorst et al. [2], the
authors suggested that continuous high-dose intravenous
(IV) furosemide was well tolerated, safe, and effective in
reducing volume overload in hemodynamically unstable
infants after CPB surgery.
Ethacrynic acid has been studied in pediatric patients
in a single IV dose form and in multiple intermittent IV
doses [21-25]. These studies used a dose of 1 mg/kg/dose.
To date, only one retrospective study has evaluated the
use of ethacrynic acid continuous infusion for >12 hours
in pediatric patients: 9 patients (including only one
neonate) received prolonged EA continuous infusion at
a dose range of 0.1-0.3 mg/kg/h [26]. However, etha-
crynic acid is considered to be 30% less potent than fur-
osemide, and is associated with a greater incidence of
ototoxicity [12].
The importance to control fluid balance and to limit
fluid overload in post operative cardiac surgery patients
Table 2 Early stoppers (ES) vs late stoppers (LS) of loop diuretic continuous infusion
ES LS p
Pts number 11 7 -
Diuretic dose (mg/kg/h) 0.14 (0.09) 0.49 (0.17) 0.0001
Weight (kg) 8.3 (7.7) 3.4 (0.8) 0.03
Aristotle score 10 (2) 11 (2) 0.09
VIS 19 (10) 23 (9) 0.04
CPB (min) 218 (83) 322 (142) 0.04
LMV (days) 3 (2) 20 (31) 0.02
LOA (days) 11 (18) 24 (25) 0.1
POD0 POD1 POD2 POD0 POD1 POD2 -
UO (ml/kg/h) 5.9 (2.7) 4.1 (2.1) 3.9 (1.9) 6.2 (6.1) 6.1 (3.4) 6.1 (1.1) 0.08
Creatinine (mg/dl) 0.5 (0.3) 0.5 (0.25) 0.5 (0.2) 0.6 (0.2) 0.6 (0.3) 0.6 (0.3) 0.17
UO/diuretic dose 38.8 (34) 41.5 (25) 40.0 (13) 14.5 (16) 20.2 (20) 11.4 (3.4) 0.0006
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studies that have associated fluid overload to suboptimal
outcomes (in terms of cardiac, pulmonary and renal
function) [4-7]. Fluid balance can be managed in such
patients by reducing administration of fluids (which is
barely possible in the immediate post operative phase
due to the high fluidic requirements for intravascular re-
placement and vasoactive drugs administration) or by in-
creasing UO.
With this background, it is evident the importance of
identifying the LD that produces the greatest UO at the
lowest dose with, possibly, reduced side effects and renal
injury.
Our findings establish a greater effect of EA on UO
and fluid balance on POD 0. During the following study
days, being the clinicians free to modify the diuretic dose
according to UO, EA dose was decreased significantly
quicker than the F group: at the end, a 30% lower EA
dose was needed to achieve a similar UO in the two
groups on each of the study days. Finally, EA was more
frequently interrupted than F likely due to a more fre-
quent achievement of negative fluid balance or polyuria
as explicitly stated by the attending physicians. Accord-
ing to these results, EA in infants appeared to be about
30% more potent than furosemide. The administration
of aggressive diuretic therapies has generated concerns
about renal safety, and some controversial results have
been published in recent years [27,28]. In our patients,
both types of LD, administered at high continuous infu-
sion for 24 to 72 hours, appeared to be safe in terms of
renal function. SCr, CysC, and NGAL levels did not
show different behaviors in the two groups. Creatinine
increased significantly from preoperative level to PCICU
admission as previously described [29]. Although pre-
operative CysC and NGAL values were not available
(collection of these biomarkers started for the purposeof exclusive study only after enrollment, at PCICU ad-
mission), their post-operative trends were not signifi-
cantly different in the two groups, and they never
reached truly pathologic levels. AKI incidence according
to pRIFLE was quite high in the two groups even if
pRIFLE classes were not significantly different for the
two groups. We can speculate that this was probably
related to the high-risk population of small patients
undergoing complex surgery; the high AKI occurrence
may be also ascribed to the high sensitivity of pRIFLE
(previous studies determined an incidence of 50-60%
AKI in small cardiac patients) [30-32]: furthermore,
about half of these patients had mild renal dysfunction,
whose association with worse outcomes has been re-
cently questioned [33]. Even if this study was not de-
signed in order to determine the association between
the dose and the renal function, it cannot be excluded
that the incidence of AKI might be associated to a high
diuretic dose. It should be also acknowledged that the
continuous infusion of the two study drugs was allowed
to be increased up to 0.8 mg/kg/h, although this is a
higher dose then what generally described elsewhere:
this was done secondary to institutional policy in the
absence of previous literature recommending the max-
imum continuous infusion doses of LD. However, only
4 patients over a total of 74 (5%) required an average
dose higher than 0.4 mg/kg/h and none of them pre-
sented short terms side effects linked to diuretic high
dose. As a matter of fact, in order to verify if an associ-
ation between diuretics and renal function we attempted a
secondary analysis comparing children who received a low
diuretic dose (during a relatively short period of continu-
ous infusion) with those who received a higher dose (and
continued the continuous infusion during the whole
study period): this small secondary analysis showed that
higher doses of infused diuretic were associated to the
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vasoactive requirements and longer CPB) rather than
renal function as evidenced by similar creatinine values
in the two groups. Finally, creatinine levels at PCICU
discharge were not increased with respect to baseline
values, likely showing that short-term high dose di-
uretics did not have long-term effects on renal func-
tion. Interestingly, the clinical effects on POD0 seem to
warrant improved hemodynamics in EA patients, since
the CI remained slightly though significantly higher,
even if it should be acknowledged that CI showed a
baseline insignificant tendency to be higher in the EA
group. An improved ventricular performance seems
likely in patients achieving timely negative fluid balance
[5]. The same benefit was identified at the lung level,
justifying a shorter mechanical ventilation time and
length of PCICU admission. Unsurprisingly, more than
two-thirds of our patients experienced at least one epi-
sode of hypokalemia or metabolic alkalosis during the
evaluated period. Interestingly, whereas incidence of
decreased potassium levels was similar in the two
groups, EA displayed a significantly higher potential for
causing metabolic alkalosis. This was probably related
to its higher effects on UO and the contraction of chil-
dren volemia. This finding is in line with the small
report by Miller and coworkers who recorded an inci-
dence of metabolic alkalosis of 55% after administration
of EA [26]. Hypochloremic metabolic alkalosis is a
common complication of LD therapy due to the loss of
extracellular fluid and chloride [34] and it is probably
overlooked in the setting of neonatal/infant critical ill-
ness: its effects would merit attention in future studies.
Limits of the study
This study has some strengths and some limitations. For
the first time, we evaluated furosemide effects on UO
compared to EA. The children in the study were a rather
homogenous population in terms of age and type of sur-
gery. In particular, we evaluated a cohort of high-risk pa-
tients (average Aristotle score above 9) with a high
incidence of (mild) post-operative AKI. Furthermore, the
enrollment occurred soon after PCICU admission from
the operatory room in order to avoid that the patients
received one or more diuretic boluses before the con-
tinuous infusion and to optimize matching of the com-
pared groups. In light of this, decision to start diuretic
continuous infusion was left to the attending clinician,
which is a rather unspecific inclusion criterion. However,
this was made deliberately because the choice of starting
continuous infusion was not changed during the study
period with respect to institutional everyday clinical
practice. The intraoperative fluid balance at PCICU ad-
mission was computed to evaluate if significant differ-
ences were present between the two populations: thiswas only an approximation because it did not include
post CPB transfusions and bleeding and it likely under-
estimated the actual degree of fluid status of our pa-
tients. Our cohort displayed a relatively high length of
PCICU admission: when considered as a whole, average
LOA of our patients was 13 days (12) and median LOA
was 9 days (5–17). Our results are in line with the “early
FO” group of Hassinger study (median LOA 9 days
(5.75–12.3) [5] and with those detailed in the higher
fluid overload tertile of Seguin’s study (average LOA of
11.7 days (7.9)) [6]. Another important limitation of this
trial is the relatively small number of patients studied.
This was due to the primary outcome that did not re-
quire a particularly large sample. It is possible that with
a greater number of patients, some of the secondary ob-
jectives, especially those related to adverse effects
(namely, metabolic alkalosis), would have been better
evaluated. Furthermore, we did not evaluate the long-
term effects of short-term high diuretic doses, such as
ototoxicity. These might be a subject of further study in
the future. To our knowledge, however, clinically relevant
long-term adverse effects such as damage to hearing func-
tion are limited to a small percentage of critically ill pa-
tients receiving long-term courses of (ototoxic) drugs.
It is unlikely that short-term LD continuous infusion
would significantly contribute to long-term clinical
sequelae.
Conclusions
In a relatively small cohort of high-risk cardiac surgery
infants, EA produced more UO compared to F on
POD0. Generally, less EA dose is required to achieve
similar UO than F. EA and furosemide appeared to be
equally safe in terms of renal function, but EA caused a
more intense metabolic alkalosis. Finally, EA patients
benefited from improved urine flow and optimized fluid
balance in terms of better CI, shorter mechanical venti-
lation, and PCICU admission time.
Key messages
 EA produced more UO compared to F on POD0.
Generally, less EA dose is required to achieve
similar UO than F.
 Ethacrynic acid and furosemide at a continuous
infusion dose from 0.2 to 0.8 mg/kg/h appear to
be equally safe in terms of renal function.
 Ethacrynic acid is responsible for a more intense
metabolic alkalosis.
 In our study, improved fluid balance warranted
by ethacrynic acid in the first post-operative day
revealed improved average cardiac output levels and,
probably, shorter duration of mechanical ventilation
and Pediatric Cardiac Intensive Care Unit stay.
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